Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Completed · Phase 4

Conditions studied: Glaucoma

In brief

A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Key facts

Study ID

NCT00811850

Run by

Allergan

People needed

15

Starts

2008-12-01

Expected to finish

2009-12-01

Last updated by the study team

2019-04-24

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: 30 years or older.
• Primary open-angle glaucoma (POAG) or ocular hypertensive in at least one eye.
• Best corrected visual acuity at least 20/40 in at least one eye.

You may not qualify if…

• History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.
• History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).
• History or signs of intraocular trauma.
• Any abnormality preventing reliable applanation tonometry.
• Current use of any ophthalmic or systemic steroid which may interfere with this investigation.
• Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.

Where it is running

• Study site — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.